$2.56
0.79% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
IL0011050551
Symbol
EVGN
Sector
Industry

Evogene Ltd Stock price

$2.56
-1.03 28.69% 1M
-4.79 65.18% 6M
-5.84 69.52% YTD
-3.39 57.00% 1Y
-25.94 91.02% 3Y
-14.29 84.81% 5Y
-130.14 98.07% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.02 0.79%
ISIN
IL0011050551
Symbol
EVGN
Sector
Industry

Key metrics

Market capitalization $12.85m
Enterprise Value $9.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.02
P/S ratio (TTM) P/S ratio 1.36
P/B ratio (TTM) P/B ratio 4.22
Revenue growth (TTM) Revenue growth 290.29%
Revenue (TTM) Revenue $9.45m
EBIT (operating result TTM) EBIT $-21.48m
Free Cash Flow (TTM) Free Cash Flow $-19.61m
Cash position $20.91m
EPS (TTM) EPS $-3.95
P/E forward negative
P/S forward 0.85
EV/Sales forward 0.64
Short interest 0.45%
Show more

Is Evogene Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Evogene Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Evogene Ltd forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Evogene Ltd forecast:

Buy
100%

Financial data from Evogene Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
9.45 9.45
290% 290%
100%
- Direct Costs 4.36 4.36
14% 14%
46%
5.09 5.09
458% 458%
54%
- Selling and Administrative Expenses 7.14 7.14
1% 1%
76%
- Research and Development Expense 17 17
7% 7%
178%
-19 -19
29% 29%
-200%
- Depreciation and Amortization 2.61 2.61
2% 2%
28%
EBIT (Operating Income) EBIT -21 -21
26% 26%
-227%
Net Profit -20 -20
13% 13%
-210%

In millions USD.

Don't miss a Thing! We will send you all news about Evogene Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evogene Ltd Stock News

Neutral
PRNewsWire
about one month ago
REHOVOT, Israel , Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a s...
Neutral
Seeking Alpha
about one month ago
Evogene Ltd. (NASDAQ:EVGN ) Q2 2024 Earnings Conference Call August 22, 2024 9:00 AM ET Company Participants Ofer Haviv - President and CEO Yaron Eldad - CFO Yoash Zohar - CEO, Casterra Dan Jacob Gelvan - CEO, AgPlenus Ltd Amit Noam - CEO, Lavie BIO Conference Call Participants Operator Welcome to Evogene's Second Quarter Results Conference Call.
Neutral
InvestorPlace
about one month ago
Evogene (NASDAQ: EVGN ) just reported results for the second quarter of 2024. Evogene reported earnings per share of -$1.06.
More Evogene Ltd News

Company Profile

Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.

Head office Israel
CEO Ofer Haviv
Employees 142
Founded 1999
Website www.evogene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today